The present invention provides novel processes, compositions, and methods for analyzing or assaying the potency and/or functionality of tumor infiltrating lymphocyte (TIL) products for use in therapy, including human cancer therapy, and analyzing or assaying the potency and/or functionality of other polyclonal products, such as marrow infiltrating lymphocyte (MIL) and peripheral blood lymphocyte (PBL) products. Compositions, methods, and kits for preparing and treating cancer using TIL, MIL, and PBL products are also provided.

The present invention relates to a mammalian FGF21 responsive reporter cell line and method of using the same for detecting and optionally quantitating FGF21 activity in a test sample. The invention further relates to a method for detecting and optionally quantitating neutralizing antibodies against FGF21 present in a test sample using the reporter cell line of the present invention.

The present disclosure relates in part to a blood-based method for the detection of a proteinopathy in a subject including, but not limited to, Alzheimer's disease (AD), mild cognitive impairment (MCI), and preeclampsia (PE), utilizing autophagy-deficient trophoblast (ADT) cells to sequester protein aggregates from the serum of said subject, and permit detection thereof. The present disclosure further relates to methods of treating, preventing, and/or ameliorating a proteinopathy in a subject by the administration of trehalose, a salt, solvate, stereoisomer, derivative, prodrug and or any mixture thereof.

According to the present invention, immortalized cells derived from porcine kidney macrophages are found to have high infection susceptibility to various African swlne fever virus strains. As a result, using the cells, it is possible to proliferate the virus and furthermore produce and detect the virus.

Embodiments of this disclosure include methods for detecting autoimmune diseases by detecting the presence of autoantibodies directed against self-antigens (or respective antoantigens). In particular, embodiments of this disclosure include detecting autoantibodies produced by B cells from a patient suspected of having an autoimmune disease using a Direct B Cell test. Other embodiments include detecting autoantibodies produced by memory B cells using a Memory B Cell test. Further embodiments include methods of treatment of a patient having an autoimmune disease comprising administering a substance that decreases B cell numbers. Other embodiments comprise treating a patient with other known treatments.

The present invention relates to a non-invasive method for generating human three-dimensional nasopharyngeal organoids, including non-invasively collecting nasopharyngeal swab samples; culturing the samples in a matrix with niche factors; and obtaining the three-dimensional human nasopharyngeal organoids after culturing the samples in the matrix for 14-21 days. The three-dimensional human nasopharyngeal organoids are then dissociated into a single cell suspension for the creation of human two-dimensional nasopharyngeal organoids. The present nasopharyngeal organoids and their preparation method enable the rapid expansion of stem cells to form organoids within a short period of time. By combining organoid passaging techniques, a sufficient number of organoids can be obtained within a limited time for research and experimental operations. These organoid models provide new and excellent tools to study the transmission, tropism, and innate host responses of emerging viruses such as influenza virus and coronavirus, aiding in the evaluation of the pathophysiological characteristics of the viruses.

The present invention relates to a method for preparing commercial scale quantities of canine functional beta cells and to the establishment of cell lines from immature canine pancreatic tissues. It also relates to a method of diagnosis using canine beta cell tumours or cells derived thereof. The method comprises sub-transplantation procedure to enrich the graft in proliferating beta cells, allowing generating canine Beta cell lines. Such lines express, produce and secrete insulin upon glucose stimulation.

The present disclosure relates to an Extra Cellular Matrix composition specific for cancer type and a tumor microenvironment platform for long term culturing of tumor tissue, wherein said culturing provides human ligands and tumor tissue micro-environment to mimic physiologically relevant signalling systems. The present disclosure further relates to the development of a Clinical Response Predictor and its application in the prognostic field (selection of treatment option for the patient) and translational biology field (development of anticancer drugs). The disclosure further relates to a method of predicting clinical response of a tumor patient to drug(s). The disclosure further relates to a method for screening tumor cells for the presence of specific markers for determining the viability of said cells for indication of tumor status.

Provided are a method for preparing reticulocyte simulating particles and platelet simulating particles, and a reference control. The method for preparing the reticulocyte simulating particles comprises: staining mammalian anucleated red blood cells having a volume of 60-120 fL with a protein fluorescent dye activated by N-hydroxysuccinimide, and fixing the anucleated red blood cells to prepare the reticulocyte simulating particles. The platelet simulating particles are prepared from mammalian anucleated red blood cells having a volume of 2-25 fL, and the steps of preparing the platelet simulating particles are the same as that for the reticulocyte simulating particles. The preparation method comprises: using an protein fluorescent dye activated by N-hydroxysuccinimide to stain mammalian anucleated red blood cells having different volumes, so as to respectively obtain reticulocyte simulating particles and platelet simulating particles. The fluorescence and volume direction thereof in the scatter diagram are similar to the scatter diagram distribution of reticulocytes, reticulated platelets and platelets in fresh blood. The prepared simulating particles have good stability and do not interfere with the counting and differentiation of other cell particles.

The present disclosure relates to an Extra Cellular Matrix composition specific for cancer type and a tumor microenvironment platform for long term culturing of tumor tissue, wherein said culturing provides human ligands and tumor tissue micro-environment to mimic physiologically relevant signalling systems. The present disclosure further relates to the development of a Clinical Response Predictor and its application in the prognostic field (selection of treatment option for the patient) and translational biology field (development of anticancer drugs). The disclosure further relates to a method of predicting clinical response of a tumor patient to drug(s). The disclosure further relates to a method for screening tumor cells for the presence of specific markers for determining the viability of said cells for indication of tumor status.